Rhodiola rosea L. and Alzheimer's Disease: From Farm to Pharmacy

Phytotherapy Research

Volumn 30, Issue 4, 2016, Pages 532-539

  Nabavi, Seyed Fazel ^a   Braidy, Nady ^b   Orhan, Ilkay Erdogan ^c   Badiee, Arash ^d   Daglia, Maria ^e   Nabavi, Seyed Mohammad ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c GAZI UNIVERSITY   (Turkey)

^d MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

Neurodegeneration; Neuroinflammation; Neurotoxicity; Oxidative stress; Rhodiola rosea

Indexed keywords

P21 ACTIVATED KINASE 1; RHODIOLA ROSEA EXTRACT; 4-HYDROXYPHENYLETHANOL; DISACCHARIDE; GLUCOSIDE; NEUROPROTECTIVE AGENT; P21 ACTIVATED KINASE; PHENETHYL ALCOHOL; PHENOL DERIVATIVE; PLANT EXTRACT; ROSAVIN; SALIDROSIDE;

ALZHEIMER DISEASE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; EXCITOTOXICITY; HUMAN; LD50; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHARMACY; PHYTOCHEMISTRY; PLANT ROOT; PRECIPITATION; REVIEW; TRADITIONAL MEDICINE; TREATMENT OUTCOME; TREATMENT PLANNING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL (TOPIC); COGNITION DISORDERS; DRUG EFFECTS; MEDICINAL PLANT; RHODIOLA;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; DISACCHARIDES; GLUCOSIDES; HUMANS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; P21-ACTIVATED KINASES; PHENOLS; PHENYLETHYL ALCOHOL; PLANT EXTRACTS; PLANT ROOTS; PLANTS, MEDICINAL; RHODIOLA;

EID: 84962835260     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5569     Document Type: Review

References (87)

1. Adamczak A, Gryszczyńska A, Buchwald W,. 2014. Biometric and phytochemical variability of roseroot (Rhodiola rosea L.) from field cultivation. Herba Pol. 60: 7-17.
2. Adaptogen APP,. 2001. Rhodiola rosea: a possible plant adaptogen. Altern Med Rev 6: 293-302.
3. Alm T,. 2004. Ethnobotany of Rhodiola rosea (Crassulaceae) in Norway. SIDA, Contrib. Bot. 321-344.
4. Ansari MA, Scheff SW,. 2010. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropath Exp Neur 69: 155-167.
5. Berchtold NC, Cotman CW,. 1998. Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiol Aging 19: 173-189.
6. Birks J,. 2006. Cholinesterase inhibitors for Alzheimer's disease (review). Cochrane Database Syst Rev 1: CD005593.
7. Brown RP, Gerbarg PL, Ramazanov Z,. 2002. Rhodiola rosea: a phytomedicinal overview. Herbalgram 56: 40-52.
8. Butterfield DA, Kanski J,. 2001. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 122: 945-962.
9. Choi DY, Lee YJ, Hong JT, Lee HJ,. 2012. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease. Brain Res Bull 87: 144-153.
10. Collingridge GL, Lester RA,. 1989. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol Rev 41: 143-210.
11. Cropley M, Banks AP, Boyle J,. 2015. The effects of Rhodiola rosea L. extract on anxiety, stress, cognition and other mood symptoms. Phytother Res. DOI: 10.1002/ptr.5486.
12. De Bock K, Eijnde BO, Ramaekers M, Hespel P,. 2004. Acute Rhodiola rosea intake can improve endurance exercise performance. Int J Sport Nutr Exerc Metab 14: 298-307.
13. Devasagayam TP, Tilak JC, Boloor KK, Sane KS, Ghaskadbi SS, Lele RD,. 2004. Free radicals and antioxidants in human health: current status and future prospects. J Assoc Physicians India 52: 794-804.
14. Feng Y, Wang X,. 2012. Antioxidant therapies for Alzheimer's disease. Oxid Med Cell Longev 2012: 472932.
15. Fiala JC, Spacek J, Harris KM,. 2002. Dendritic spine pathology: cause or consequence of neurological disorders? Brain Res Brain Res Rev 39: 29-54.
16. Furmanowa M, Oledzka H, Michalska M, Sokolnicka I, Radomska D,. 1995. Rhodiola rosea L.(Roseroot): In vitro regeneration and the biological activity of roots. In Medicinal and Aromatic Plants VIII. Springer: Berlin, Germany; 412-426.
17. Galambosi B,. 2006. Demand and availability of Rhodiola rosea raw material. Frontis 17: 223-236.
18. Galambosi B, Galambosi Z, Uusitalo M, Heinonen A,. 2009. Effects of plant sex on the biomass production and secondary metabolites in roseroot (Rhodiola rosea L.) from the aspect of cultivation. Z Arznei-Gewurzpfla 14: 114-121.
19. Galasko DR, Peskind E, Clark CM, et al., 2012. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69: 836-841.
20. Gautron L, Lafon P, Chaigniau M, Tramu G, Laye S,. 2002. Spatiotemporal analysis of signal transducer and activator of transcription 3 activation in rat brain astrocytes and pituitary following peripheral immune challenge. Neuroscience 112: 717-729.
21. Gerbarg PL, Illig PA, Brown RP,. 2014. Rhodiola rosea 10 in Psychiatric and Medical Practice. Rhodiola rosea. CRC Press: Boca Raton, USA; 225.
22. Gibbs RB, Aggarwal P,. 1998. Estrogen and basal forebrain cholinergic neurons: implications for brain aging and Alzheimer's disease-related cognitive decline. Horm Behav 34: 98-111.
23. Goldstein MS, Chen CW, Mammone T, Gan DC,. 2008. Cosmetic compositions and methods comprising Rhodiola rosea. Google Patents.
24. Gonzalez-Scarano F, Baltuch G,. 1999. Microglia as mediators of inflammatory and degenerative diseases. Ann Rev Neurosci 22: 219-240.
25. Griffin WST, Stanley LC, Ling C, et al., 1989. Brain Interleukin-1 and S-100 immunoreactivity are elevated in down syndrome and Alzheimer-disease. Proc Natl Acad Sci U S A 86: 7611-7615.
26. Hartwich M,. 2010. The importance of immunological studies on Rhodiola rosea in the new effective and safe herbal drug discovery. Centr Eur J Immunol 35: 263-266.
27. Hayashi ML, Choi SY, Rao BS, Jung HY, Lee HK, Zhang D,. 2004. Altered cortical synaptic morphology and impaired memory consolidation in forebrain-specific dominant-negative PAK transgenic mice. Neuron 42: 773-787.
28. Hensley K,. 2010. Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimer's Dis 21: 1-14.
29. Hernández-Santana A, Pérez-López V, Zubeldia JM, Jiménez-del-Rio M,. 2014. A Rhodiola rosea root extract protects skeletal muscle cells against chemically induced oxidative stress by modulating heat shock protein 70 (HSP70) expression. Phytother Res 28: 623-628.
30. Ishaque S, Shamseer L, Bukutu C, Vohra S,. 2012. Rhodiola rosea for physical and mental fatigue: a systematic review. BMC Complement Altern Med 12: 70.
31. Jeong HJ, Ryu YB, Park SJ, et al., 2009. Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem 17: 6816-6823.
32. Junttila MR, Li SP, Westermarck J,. 2008. Phosphatase-mediated crosstalk between MAPK signalling pathways in the regulation of cell survival. FASEB J 22: 954-965.
33. Khanum F, Bawa AS, Singh B,. 2005. Rhodiola rosea: a versatile adaptogen. Compr Rev Food Sci Food Saf 4: 55-62.
34. Kichina JV, Goc A, Al-Husein B, Somanath PR, Kandel ES,. 2010. PAK1 as a therapeutic target. Expert Opin Ther Targets 14: 703-725.
35. Kucinskaite A, Pobłocka-Olech L, Krauze-Baranowska M, Sznitowska M, Savickas A, Briedis V,. 2006. Evaluation of biologically active compounds in roots and rhizomes of Rhodiola rosea L. cultivated in Lithuania. Medicina 43: 487-494.
36. Kurkin V, Zapesochnaya G, Dubichev A, Vorontsov E, Aleksandrova I, Panova R,. 1991. Phenylpropanoids of a callus culture of Rhodiola rosea. Chem Nat Comp 27: 419-425.
37. Kylin M, 2010. Genetic diversity of roseroot (Rhodiola rosea L.) from Sweden, Greenland and Faroe Islands. http://urn.kb.se/resolve?urn=urn:nbn:se:slu:epsilon-4-352
38. Lee Y, Jung JC, Jang S, et al., 2013. Anti-inflammatory and neuroprotective effects of constituents isolated from Rhodiola rosea. Evid Based Compl Alt 2013: 514049.
39. Li HB, Ge YK, Zheng XX, Zhang L,. 2008. Salidroside stimulated glucose uptake in skeletal muscle cells by activating AMP-activated protein kinase. Eur J Pharmacol 588: 165-169.
40. Li H, Sze S, Tong Y, Ng T,. 2009. Production of Th1-and Th2-dependent cytokines induced by the Chinese medicine herb, Rhodiola algida, on human peripheral blood monocytes. J Ethnopharmacol 123: 257-266.
41. Lindsay J, et al., 2002. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156: 445-453.
42. Linné CV,. 2005. 1749. Materia Medica. Liber I. de Plantis.: Stockholm: Laurentius Salvius; 168.
43. Ma G, Li W, Dou D, et al., 2006. Rhodiolosides AE, monoterpene glycosides from Rhodiola rosea. Chem Pharm Bull 54: 1229-1233.
44. Mamedov N, Gardner Z, Craker LE,. 2005. Medicinal plants used in Russia and Central Asia for the treatment of selected skin conditions. J Herbs Spices Med Plants 11: 191-222.
45. Maruta H,. 2014. Herbal therapeutics that block the oncogenic kinase PAK1: a practical approach towards PAK1-dependent diseases and longevity. Phytother Res 28: 656-672.
46. McGeer EG, McGeer PL,. 1999. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharm Des 5: 821-836.
47. Mecocci P, Polidori MC,. 2012. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim Biophys Acta 1822: 631-638.
48. Ming DS, Hillhouse BJ, Guns ES, et al., 2005. Bioactive compounds from Rhodiola rosea (Crassulaceae). Phytother Res 19: 740-743.
49. Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF, Morrow JD,. 2005. F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal 7: 269-275.
50. Nabavi SF, Nabavi SM, Mirzaei M, Moghaddam AH,. 2012a. Protective effect of quercetin against sodium fluoride induced oxidative stress in rat's heart. Food Funct 3: 437-441.
51. Nabavi SF, Nabavi SM, Moghaddam AH, Naqinezhad A, Bigdellou R, Mohammadzadeh S,. 2012b. Protective effects of Allium paradoxum against gentamicin-induced nephrotoxicity in mice. Food Funct 3: 28-29.
52. Nabavi SF, Nabavi SM, Ebrahimzadeh MA, Jafari N, Yazdanpanah S,. 2013a. Biological activities of freshwater algae, Spirogyra singularis Nordstedt. J Aquat Food Prod Technol 22: 58-65.
53. Nabavi SF, et al., 2013b. Hepatoprotective effect of gallic acid isolated from Peltiphyllum peltatum against sodium fluoride-induced oxidative stress. Ind Crops Prod 44: 50-55.
54. Nabavi SF, Daglia M, Moghaddam AH, Habtemariam S, Nabavi SM,. 2014. Curcumin and liver disease: from chemistry to medicine. Compr Rev Food Sci Food Safe 13: 62-77.
55. Nabavi SF, Dean O, Turner A, Sureda A, Daglia M, Nabavi S,. 2015a. Oxidative stress and post-stroke depression: possible therapeutic role of polyphenols? Curr Med Chem 22 (3): 343-351.
56. Nabavi SF, Habtemariam S, Daglia M, Shafighi N, Barber A, Nabavi S,. 2015b. Anthocyanins as a potential therapy for diabetic retinopathy. Curr Med Chem 22 (1): 51-58.
57. Nabavi SM, Marchese A, Izadi M, Curti V, Daglia M, Nabavi SF,. 2015c. Plants belonging to the genus Thymus as antibacterial agents: From farm to pharmacy. Food Chem 173: 339-347.
58. Nabavi SF, Russo GL, Daglia M, Nabavi SM,. 2015d. Role of quercetin as an alternative for obesity treatment: you are what you eat!. Food Chem 179: 305-310.
59. Olney JW, Ho OL, Rhee V,. 1971. Cytotoxic effects of acidic and sulphur containing amino acids on the infant mouse central nervous system. Exp Brain Res 14: 61-76.
60. Panossian AG,. 2003. Adaptogens: tonic herbs for fatigue and stress. Altern Complement Ther 9: 327-331.
61. Panossian A, Wikman G, Sarris J,. 2010. Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine 17: 481-493.
62. Patel RP, Moellering D, Murphy-Ullrich J, Jo H, Beckman JS, Darley-Usmar VM,. 2000. Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med 28: 1780-1794.
63. Platikanov S, Evstatieva L,. 2008. Introduction of wild golden root (Rhodiola rosea L.) as a potential economic crop in Bulgaria. Econ Bot 62: 621-627.
64. Pratico D, Sung S,. 2004. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J Alzheimers Dis 6: 171-175.
65. Praticò D, Lee VMY, Trojanowski JQ, Rokach J, Fitzgerald GA,. 1998. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12: 1777-1783.
66. Ramakers GJ,. 2002. Rho proteins, mental retardation and the cellular basis of cognition. Trends Neurosci 25: 191-199.
67. Reitz C, Brayne C, Mayeux R,. 2011. Epidemiology of Alzheimer disease. Nat Rev Neurol 7: 137-152.
68. Rogers J, Lubernarod J, Styren SD, Civin WH,. 1988. Expression of immune system-associated antigens by cells of the human central nervous-system-relationship to the pathology of alzheimers-disease. Neurobiol Aging 9: 339-349.
69. Rohloff J,. 2002. Volatiles from rhizomes of Rhodiola rosea L. Phytochemistry 59: 655-661.
70. Sandberg F, Bohlin L,. 1993. Fytoterapi: växtbaserade läkemedel. Hälsokostrådet: Stockholm.
71. Skopińska-Rózewska E, Malinowski M, Wasiutyński A,. 2008. The influence of Rhodiola quadrifida 50% hydro-alcoholic extract and salidroside on tumor-induced angiogenesis in mice. Pol J Vet Sci 11: 97-104.
72. Stadtman ER, Berlett BS,. 1997. Reactive oxygen-mediated protein oxidation in aging and disease. Chem Res Toxicol 10: 485-494.
73. Tolonen A, Uusitalo J,. 2004. Fast screening method for the analysis of total flavonoid content in plants and foodstuffs by high-performance liquid chromatography/electrospray ionization time-of-flight mass spectrometry with polarity switching. Rapid Commun Mass Spectrom 18: 3113-3122.
74. Tolonen A, Pakonen M, Hohtola A, Jalonen J,. 2003. Phenylpropanoid glycosides from Rhodiola rosea. Chem Pharm Bull 51: 467-470.
75. Toyokuni S,. 1999. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 49: 91-102.
76. Troshchenko A, Kutikova G,. 1967. Rhodioloside from Rhodiola rosea and Rh. quadrifida. I. Chem Nat Comp 3: 204-207.
77. Udintsev SN, Schakhov VP,. 1991. Decrease of cyclophosphamide haematotoxicity by Rhodiola rosea root extract in mice with Ehrlich and Lewis transplantable tumours. Eur J Cancer Clin Oncol 27: 1182.
78. Uyeturk U, Terzi EH, Gucuk A, Kemahli E, Ozturk H, Tosun M,. 2013. Prevention of torsion-induced testicular injury by Rhodiola rosea. Urology 82: 254. e251-254. e256.
79. Van Diermen D, Marston A, Bravo J, Reist M, Carrupt PA, Hostettmann K,. 2009. Monoamine oxidase inhibition by Rhodiola rosea L. roots. J Ethnopharmacol 122: 397-401.
80. Webster B, et al., 2006. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J Neuropath Exp Neur 65: 142-151.
81. Wiedenfeld H, Dumaa M, Malinowski M, Furmanowa M, Narantuya S,. 2007. Phytochemical and analytical studies of extracts from Rhodiola rosea and Rhodiola quadrifida. Pharmazie 62: 308-311.
82. Wiegant FA, Surinova S, Ytsma E,. 2009. Plant adaptogens increase lifespan and stress resistance in C. elegans. Biogerontology 10: 27-42.
83. Yankner BA,. 1996. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16: 921-932.
84. Yu BP,. 1994. Cellular defenses against damage from reactive oxygen species. Physiol Rev 74: 139-162.
85. Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, Lim GP,. 2006. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci 9: 234-242.
86. Zhou Q, Yin ZP, Ma L, Zhao W, Hao HW, Li HL,. 2014. Free radical-scavenging activities of oligomeric proanthocyanidin from Rhodiola rosea L. and its antioxidant effects in vivo. Nat Prod Res 28: 2301-2303.
87. Zhu C, Guan F, Wang C, Jin LH,. 2014. The protective effects of Rhodiola crenulata extracts on Drosophila melanogaster gut immunity induced by bacteria and SDS toxicity. Phytother Res 28: 1861-1866.